BCRX Relative Valuation
BCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCRX is overvalued; if below, it's undervalued.
Historical Valuation
BioCryst Pharmaceuticals Inc (BCRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -32.66. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.88
Fair
28.40
PE
1Y
3Y
5Y
Trailing
Forward
23.55
EV/EBITDA
BioCryst Pharmaceuticals Inc. (BCRX) has a current EV/EBITDA of 23.55. The 5-year average EV/EBITDA is -8.22. The thresholds are as follows: Strongly Undervalued below -133.14, Undervalued between -133.14 and -70.68, Fairly Valued between 54.24 and -70.68, Overvalued between 54.24 and 116.70, and Strongly Overvalued above 116.70. The current Forward EV/EBITDA of 23.55 falls within the Historic Trend Line -Fairly Valued range.
18.33
EV/EBIT
BioCryst Pharmaceuticals Inc. (BCRX) has a current EV/EBIT of 18.33. The 5-year average EV/EBIT is 9.76. The thresholds are as follows: Strongly Undervalued below -117.52, Undervalued between -117.52 and -53.88, Fairly Valued between 73.40 and -53.88, Overvalued between 73.40 and 137.04, and Strongly Overvalued above 137.04. The current Forward EV/EBIT of 18.33 falls within the Historic Trend Line -Fairly Valued range.
2.56
PS
BioCryst Pharmaceuticals Inc. (BCRX) has a current PS of 2.56. The 5-year average PS is 6.83. The thresholds are as follows: Strongly Undervalued below -4.62, Undervalued between -4.62 and 1.11, Fairly Valued between 12.55 and 1.11, Overvalued between 12.55 and 18.27, and Strongly Overvalued above 18.27. The current Forward PS of 2.56 falls within the Historic Trend Line -Fairly Valued range.
25.24
P/OCF
BioCryst Pharmaceuticals Inc. (BCRX) has a current P/OCF of 25.24. The 5-year average P/OCF is -12.97. The thresholds are as follows: Strongly Undervalued below -72.23, Undervalued between -72.23 and -42.60, Fairly Valued between 16.66 and -42.60, Overvalued between 16.66 and 46.28, and Strongly Overvalued above 46.28. The current Forward P/OCF of 25.24 falls within the Overvalued range.
13.02
P/FCF
BioCryst Pharmaceuticals Inc. (BCRX) has a current P/FCF of 13.02. The 5-year average P/FCF is 1.28. The thresholds are as follows: Strongly Undervalued below -159.54, Undervalued between -159.54 and -79.13, Fairly Valued between 81.69 and -79.13, Overvalued between 81.69 and 162.10, and Strongly Overvalued above 162.10. The current Forward P/FCF of 13.02 falls within the Historic Trend Line -Fairly Valued range.
BioCryst Pharmaceuticals Inc (BCRX) has a current Price-to-Book (P/B) ratio of -4.26. Compared to its 3-year average P/B ratio of -3.79 , the current P/B ratio is approximately 12.32% higher. Relative to its 5-year average P/B ratio of -13.01, the current P/B ratio is about -67.24% higher. BioCryst Pharmaceuticals Inc (BCRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -5.75%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.23% , the current FCF yield is about -100.00% lower.
-4.25
P/B
Median3y
-3.79
Median5y
-13.01
2.90
FCF Yield
Median3y
-5.75
Median5y
-6.23
Competitors Valuation Multiple
The average P/S ratio for BCRX's competitors is 0.00, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 36.14%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BCRX increased by 4.12% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -73.38 to -172.78.
The secondary factor is the Revenue Growth, contributed 36.14%to the performance.
Overall, the performance of BCRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is BioCryst Pharmaceuticals Inc (BCRX) currently overvalued or undervalued?
What is BioCryst Pharmaceuticals Inc (BCRX) fair value?
How does BCRX's valuation metrics compare to the industry average?
What is the current P/B ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Dec 05 2025?
What is the current FCF Yield for BioCryst Pharmaceuticals Inc (BCRX) as of Dec 05 2025?
What is the current Forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Dec 05 2025?